First National Bank of Mount Dora Trust Investment Services Has $1.42 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

First National Bank of Mount Dora Trust Investment Services lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 63.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,301 shares of the medical research company’s stock after selling 3,942 shares during the period. First National Bank of Mount Dora Trust Investment Services’ holdings in Thermo Fisher Scientific were worth $1,423,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. PDS Planning Inc grew its stake in Thermo Fisher Scientific by 4.0% in the third quarter. PDS Planning Inc now owns 2,291 shares of the medical research company’s stock valued at $1,417,000 after acquiring an additional 89 shares during the period. QRG Capital Management Inc. grew its stake in Thermo Fisher Scientific by 58.0% in the third quarter. QRG Capital Management Inc. now owns 43,832 shares of the medical research company’s stock valued at $27,113,000 after acquiring an additional 16,090 shares during the period. Asset Management One Co. Ltd. grew its stake in Thermo Fisher Scientific by 0.3% in the third quarter. Asset Management One Co. Ltd. now owns 179,545 shares of the medical research company’s stock valued at $111,061,000 after acquiring an additional 485 shares during the period. National Pension Service lifted its holdings in shares of Thermo Fisher Scientific by 14.4% in the third quarter. National Pension Service now owns 702,529 shares of the medical research company’s stock valued at $434,563,000 after purchasing an additional 88,208 shares in the last quarter. Finally, Cohen Capital Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 0.7% in the third quarter. Cohen Capital Management Inc. now owns 57,344 shares of the medical research company’s stock valued at $35,471,000 after purchasing an additional 420 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the sale, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now owns 121,192 shares of the company’s stock, valued at approximately $67,175,513.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,300 shares of company stock worth $6,831,268 in the last ninety days. 0.34% of the stock is owned by company insiders.

Analyst Ratings Changes

TMO has been the topic of a number of recent analyst reports. Royal Bank of Canada dropped their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. UBS Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Bernstein Bank lifted their price target on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a report on Tuesday, October 22nd. Raymond James lifted their price target on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Finally, JPMorgan Chase & Co. upped their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $649.33.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $2.33 during trading on Monday, hitting $555.59. 170,320 shares of the stock traded hands, compared to its average volume of 1,460,317. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The stock has a market cap of $212.23 billion, a price-to-earnings ratio of 34.98, a PEG ratio of 3.61 and a beta of 0.79. The firm’s fifty day moving average is $599.39 and its 200-day moving average is $583.76. Thermo Fisher Scientific Inc. has a 52 week low of $437.26 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company’s revenue was up .2% on a year-over-year basis. During the same period in the prior year, the company earned $5.69 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.